Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? "The Pro Position".
Clinical remission
Crohn's disease
Disease assessment
Mucosal healing
Treatment targets
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
25
08
2021
accepted:
06
09
2021
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Crohn's disease (CD) is a chronic inflammatory disorder affecting the gastrointestinal tract with disease behaviour based on the depth and severity of mucosal injury. Cumulative injury can result in complications including stricture formation and penetrating complications which often require surgical resection of diseased segments of the intestine resulting in significant morbidity. Accurate assessment of disease activity and appropriate treatment is essential in preventing complications. Treatment targets in the management of CD have evolved with the advent of more potent immunosuppressive therapy. Targeting the resolution of sub-clinical inflammation and achieving mucosal healing is associated with the prevention of stricturing and penetrating complications. Identifying non-invasive modalities to assess mucosal healing remains a challenge. Mucosal healing minimizes the risk of developing disease complications, prolongs steroid-free survival, and reduces hospitalization and the need for surgical intervention.
Sections du résumé
BACKGROUND
BACKGROUND
Crohn's disease (CD) is a chronic inflammatory disorder affecting the gastrointestinal tract with disease behaviour based on the depth and severity of mucosal injury. Cumulative injury can result in complications including stricture formation and penetrating complications which often require surgical resection of diseased segments of the intestine resulting in significant morbidity. Accurate assessment of disease activity and appropriate treatment is essential in preventing complications.
SUMMARY
CONCLUSIONS
Treatment targets in the management of CD have evolved with the advent of more potent immunosuppressive therapy. Targeting the resolution of sub-clinical inflammation and achieving mucosal healing is associated with the prevention of stricturing and penetrating complications. Identifying non-invasive modalities to assess mucosal healing remains a challenge.
KEY MESSAGES
CONCLUSIONS
Mucosal healing minimizes the risk of developing disease complications, prolongs steroid-free survival, and reduces hospitalization and the need for surgical intervention.
Identifiants
pubmed: 35224016
doi: 10.1159/000519521
pii: iid-0007-0036
pmc: PMC8820165
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
36-41Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Inflamm Bowel Dis. 2015 Oct;21(10):2254-61
pubmed: 26197446
Am J Gastroenterol. 2015 Jun;110(6):802-19; quiz 820
pubmed: 25964225
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):466-473
pubmed: 31365486
Gut. 2007 Apr;56(4):453-5
pubmed: 17369375
Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):319-330
pubmed: 30791776
Aliment Pharmacol Ther. 2015 Apr;41(8):734-46
pubmed: 25728587
Inflamm Bowel Dis. 2004 Sep;10(5):661-5
pubmed: 15472532
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2256-2261
pubmed: 31743755
Inflamm Bowel Dis. 2015 Feb;21(2):331-6
pubmed: 25625487
Aliment Pharmacol Ther. 2011 Oct;34(8):911-22
pubmed: 21883326
J Gastrointestin Liver Dis. 2018 Sep;27(3):299-306
pubmed: 30240474
Clin Gastroenterol Hepatol. 2011 May;9(5):421-7.e1
pubmed: 21334460
Gastroenterology. 1990 Apr;98(4):811-8
pubmed: 2179031
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
Am J Gastroenterol. 2010 Jan;105(1):162-9
pubmed: 19755969
Aliment Pharmacol Ther. 2012 Mar;35(5):568-76
pubmed: 22251435
Gastroenterology. 2002 Feb;122(2):512-30
pubmed: 11832465
Curr Drug Targets. 2013 Nov;14(12):1460-70
pubmed: 24060148
Inflamm Bowel Dis. 2017 Jun;23(6):894-902
pubmed: 28511198
Gastroenterology. 2020 Jul;159(1):139-147
pubmed: 32224129
Lancet. 2018 Dec 23;390(10114):2779-2789
pubmed: 29096949
Gastroenterology. 2021 Sep;161(3):853-864.e13
pubmed: 34052277
Gastrointest Endosc. 2006 Mar;63(3):433-42; quiz 464
pubmed: 16500392
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15
pubmed: 24983982
Dig Dis. 2018;36(3):184-193
pubmed: 29514146
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
pubmed: 16472588
Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5
pubmed: 23856361
Clin Gastroenterol Hepatol. 2008 Nov;6(11):1218-24
pubmed: 18799360
J Crohns Colitis. 2013 Dec;7(12):e641-51
pubmed: 23810085
Gastroenterology. 2010 Feb;138(2):463-8; quiz e10-1
pubmed: 19818785
Lancet. 2002 May 4;359(9317):1541-9
pubmed: 12047962
Inflamm Bowel Dis. 2008 Jan;14(1):40-6
pubmed: 18022866
Gastroenterology. 2013 Nov;145(5):978-986.e5
pubmed: 23954314
Dig Liver Dis. 2014 Nov;46(11):974-9
pubmed: 25096964
Acta Gastroenterol Belg. 2014 Mar;77(1):41-6
pubmed: 24761690
Gut. 2005 Feb;54(2):237-41
pubmed: 15647188
Gastroenterology. 2021 Apr;160(5):1570-1583
pubmed: 33359090